HuGE Literature Finder
Records
1
-
30
| Characterization of myeloproliferative neoplasms in the paediatric and young adult population. British journal of haematology 2023 1 . Harris Zoey, Kaizer Hannah, Wei Aria, Karantanos Theodoros, Williams Donna M, Chaturvedi Shruti, Jain Tania, Resar Linda, Moliterno Alison R, Braunstein Evan |
| Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan. American journal of clinical pathology 2023 3 . Kuo Ming-Chung, Chuang Wen-Yu, Chang Hung, Lin Tung-Huei, Wu Jin-Hou, Lin Tung-Liang, Ou Che-Wei, Hung Yu-Shin, Huang Ting-Yu, Huang Ying-Jung, Wang Po-Nan, Shih Lee-Yu |
| Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL. Technology in cancer research & treatment 2023 2 22 15330338231154092. Wang Yan, Ran Fei, Lin Jin, Zhang Jing, Ma D |
| Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2 mutation. Research and practice in thrombosis and haemostasis 2023 3 7 (2): 100060. Guy Alexandre, Helzy Khalil, Mansier Olivier, Bordet Jean-Claude, Rivière Etienne, Fiore Mathieu, James Chl |
| Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia. Hematology reports 2022 Aug 14 (3): 265-269. Santoro Marco, Accurso Vincenzo, Mancuso Salvatrice, Napolitano Mariasanta, Mattana Marta, Vajana Giorgia, Russello Federica, Siragusa Serg |
| Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia. Journal of clinical laboratory analysis 2022 Jun e24522. Abdelghani Maroua, Hammami Haifa, Zidi Wiem, Amouri Hassiba, Othmen Hind Ben Hadj, Farrah Ahlem, Menif Sam |
| [Analysis of DNA Methylation Gene Mutations and Clinical Features in Patients with Myeloproliferative Neoplasm]. Zhongguo shi yan xue ye xue za zhi 2022 4 30 (2): 522-528. Wang Zi-Qing, Li Yu-Jin, Wang De-Hao, Yang Er-Peng, Li Yu-Meng, Niu Ji-Cong, Sun Ming-Qian, Chen Zhuo, Liu Wei-Yi, Hu Xiao-M |
| Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood cancer journal 2022 3 12 (3): 44. Gangat Naseema, Jadoon Yamna, Szuber Natasha, Hanson Curtis A, Wolanskyj-Spinner Alexandra P, Ketterling Rhett P, Pardanani Animesh, Tefferi Ayal |
| Vascular Endothelial Dysfunction in Myeloproliferative Neoplasms and Gene Mutations. International heart journal 2022 7 63 (4): 661-668. Aoyama Rie, Kubota Yoshiaki, Tara Shuhei, Wakita Satoshi, Yamaguchi Hiroki, Shimizu Wataru, Takano Hitos |
| von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. European journal of haematology 2022 9 109 (6): 779-786. Iizuka Kazuhide, Morishita Soji, Nishizaki Yuji, Iizuka Yoshikazu, Iriyama Noriyoshi, Ochiai Tomonori, Yanagisawa Naotake, Yasuda Hajime, Ando Jun, Gotoh Akihiko, Takei Masami, Hatta Yoshihiro, Nakamura Hideki, Nakayama Tomohiro, Komatsu Nor |
| Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report. Leukemia research reports 2021 5 15 100243. Morsia E, Goteri G, Torre E, Garvey K B, Discepoli G, Tassoni A, Mancini S, Giantomassi F, Poloni A, Olivieri A, Rupoli |
| Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical lymphoma, myeloma & leukemia 2021 4 21 (7): 483-488. Alshemmari Salem H, Rajan Reshmi, Ameen Reem, Almazyad Mazy |
| Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm. Acta haematologica 2021 7 145 (1): 30-37. Barosi Giovanni, Rosti Vittorio, Massa Margherita, Campanelli Rita, Villani Laura, Catarsi Paolo, Carolei Adriana, Abbà Carlotta, Lodigiani Corrado, Primignani Massimo, Gregato Giuliana, Bertolini Francesco, Magrini Umberto, Gale Robert Pet |
| VEGFA rs3025020 Polymorphism Contributes to CALR -Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH open : companion journal to thrombosis and haemostasis 2021 11 5 (4): e513-e520. Villani Laura, Rosti Vittorio, Massa Margherita, Campanelli Rita, Catarsi Paolo, Carolei Adriana, Abbà Carlotta, de Silvstri Annalisa, Gale Robert Peter, Barosi Giovan |
| The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study. European journal of haematology 2020 Dec . Pérez Encinas Manuel M, Sobas Marta, Gómez-Casares María Teresa, Abuin Blanco Aitor, Noya Pereira María Soledad, Raya José María, Andrade-Campos Marcio Miguel, Álvarez Larrán Alberto, Lewandowki K, Lukasz Szukalski, Hernández Boluda Juan Carlos, Ferrer-Marín Francisca, Fox María Laura, Golos Aleksandra, Gasior Kabat Mercedes, Magro Mazo Elena, Czyz Anna, Martín Martín Alejandro, Bellosillo Paricio Beatriz, Quinteiro García Celsa, González Martín Jesús María, Stuckey Ru |
| Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. Journal of hepatology 2020 Jul . Magaz Marta, Alvarez-Larrán Alberto, Colomer Dolors, López-Guerra Mónica, García-Criado M Ángeles, Mezzano Gabriel, Belmonte Ernest, Olivas Pol, Soy Guillem, Cervantes Francisco, Darnell Anna, Ferrusquía-Acosta José, Baiges Anna, Turon Fanny, Hernández-Gea Virginia, García-Pagán Juan Carl |
| Thrombophilic Risk of Factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin Mutations in Essential Thrombocythemia Egyptian Patients. Advances in hematology 2020 2020 7695129. El-Ghonemy Mohamed S, El Sharawy Solafa, Fahmi Maryan Waheeb, El-Ashwah Shaimaa, Denewer May, El-Baiomy M |
| A Novel Pathogenic CALR Exon 9 Mutation in a Patient with Essential Thrombocythemia. Laboratory medicine 2019 10 51 (3): 306-309. Lee Jee-Soo, Kim Ho Young, Kim Miyoung, Lee Young Kyu |
| Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors. Medical oncology (Northwood, London, England) 2018 Aug 35 (9): 119. Helbig Grzego |
| Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis. Thrombosis research 2018 May 167 96-103. Li Miaomiao, De Stefano Valerio, Song Tingxue, Zhou Xinmiao, Guo Zeqi, Zhu Jia, Qi Xingsh |
| Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of hepatology 2017 May . Poisson Johanne, Plessier Aurélie, Kiladjian Jean-Jacques, Turon Fanny, Cassinat Bruno, Andreoli Annalisa, De Raucourt Emmanuelle, Goria Odile, Zekrini Kamal, Bureau Christophe, Lorre Florence, Cervantes Francisco, Colomer Dolors, Durand François, Garcia-Pagan Juan-Carlos, Casadevall Nicole, Valla Dominique-Charles, Rautou Pierre-Emmanuel, Marzac Christophe, |
| [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance]. Zhongguo shi yan xue ye xue za zhi 2017 Feb 25 (1): 151-156. Tang Qin, Zhang Xiu-Wen, Xia Lei, Jiang Nai- |
| Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. Journal of hematology & oncology 2017 Feb 10 (1): 54. Lussana Federico, Carobbio Alessandra, Salmoiraghi Silvia, Guglielmelli Paola, Vannucchi Alessandro Maria, Bottazzi Barbara, Leone Roberto, Mantovani Alberto, Barbui Tiziano, Rambaldi Alessand |
| Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2 mutations and laboratory findings: a meta-analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Feb . Saki N, Shirzad R, Rahim F, Saki Malehi |
| [Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease]. Terapevticheskii arkhiv 2017 89 (7): 4-9. Melikyan A L, Subortseva I N, Sudarikov A B, Kovrigina A M, Gilyazitdinova E A, Kolosheinova T I, Abdullaev A O, Treglazova S |
| Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic proceedings 2017 8 92 (8): 1283-1290. Tefferi Ayalew, Vannucchi Alessandro Mar |
| Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. Clinical advances in hematology & oncology : H&O 2017 9 15 (9): 700-707. Maffioli Margherita, Mora Barbara, Passamonti Frances |
| Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Annals of hematology 2016 Sep . Kourie Hampig Raphael, Ameye Lieveke, Paesmans Marianne, Bron Dominiq |
| Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 2016 Jul . Min-Gu Kang, Hyun-Woo Choi, Jun Hyung Lee, Yong Jun Choi, Hyun-Jung Choi, Jong-Hee Shin, Soon-Pal Suh, Szardenings Michael, Hye-Ran Kim, Myung-Geun Sh |
| Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2016 12 129 (6): 680-692. Rumi Elisa, Cazzola Mar |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 16, 2023
- Content source: